BioTissue Appoints Rocco Venezia, CPA, as Chief Financial Officer

MIAMI, October 5, 2026 — BioTissue, a leader in regenerative healing across the ocular surface disease continuum, today announced the appointment of Rocco Venezia, CPA, as Chief Financial Officer. Venezia succeeds longtime BioTissue CFO Mike Cornelius, who retires after 13 years of service to the company.

Venezia joins BioTissue from Intercept Pharmaceuticals, where he most recently served as Chief Financial Officer and led enterprise-wide finance operations, strategic planning, capital management, and financial transformation initiatives. During his 10-year tenure at Intercept, he progressed through several leadership roles, including Corporate Controller, before being named CFO.

Throughout his career, Venezia has led fundraising efforts exceeding $1.3 billion, supported IPO and M&A transactions, and partnered closely with executive leadership teams and boards to support sustainable growth and operational excellence. Prior to Intercept, he held finance and accounting leadership positions at Mallinckrodt Pharmaceuticals and KPMG. He earned a Bachelor of Science in Accounting from Kean University.

“Rocco brings a depth of financial and operational experience that will be incredibly valuable as BioTissue continues to grow,” said Ted Davis, President and CEO of BioTissue. “His perspective will help us continue building a strong, sustainable organization that can advance our mission of empowering eye care professionals and improving healing outcomes.”

“I’m excited to join BioTissue at such an important point in the company’s journey,” said Venezia. “BioTissue has built a strong foundation around improving outcomes for patients and eye care professionals, and I look forward to partnering with the team to help support the company’s continued growth and long-term success.”

For more information, visit BioTissue.com.

Rocco Venezia, Chief Financial Officer, BioTissue

# # #

About BioTissue Holdings, Inc.
BioTissue® is an emerging biotechnology company and leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, specializing in acute and chronic ocular surface conditions. BioTissue’s portfolio of cryopreserved amniotic membrane products are processed using its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with Investigational New Drug (IND) applications as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 1.2 million human procedures with its products and published over 440 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at www.biotissue.com/.

Media Contact
Wendy Boyce
McDougall Communications for BioTissue
[email protected]
585-752-5805